27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
< 0.001] total scores differed significantly between groups, with controls (median MoCA 28.5, 95% CI 28.0-29.0; median MMSE 30, 95% CI 30.0-30.0) outperforming prodromal (median MoCA 26, 95% CI 23.0-27.0; median MMSE 29, 95% CI 27.5-29.5) and symptomatic (median MoCA 20.5, 95% CI 17.0-24.0; median MMSE 26, 95% CI 23.5-29.0) carriers. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 9,361 randomized participants, 7,221 (77%) were eligible to be re-contacted. 5 key findings →
Participants: 248 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 5 721 711 patients (3 302 579 female and 2 419 132 male) with incident dementia between 2014 and 2021 were included in the study. 5 key findings →
Design: cohort study Participants: 711 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
One hundred forty-nine carers enrolled in the study. 5 key findings →
Design: randomized controlled trial Participants: 149 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The intervention group showed less discomfort (-1.06; 95% confidence interval [CI] = -1.88 to -0.23) and fewer sentinel events (-0.40; 95% CI = -0.64 to -0.16), specifically pneumonia (-0.08; 95% CI = -0.14, -0.02). 5 key findings →
Design: randomized controlled trial Participants: 116 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 736 patients (245 [33%] female, mean age 68·0 years [SD 11·2], median admission National Institutes of Health Stroke Scale (NIHSS) 3 [IQR 1-5]), 557 (76%) were followed up until death or the end of the study, and 706 (96%) contributed to the PSD analysis. 5 key findings →
Design: prospective cohort Participants: 736 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 1,979,509 participants (mean age, 49.0 years; 51.3% men; 50.7% with MetS) were included. 5 key findings →
Design: cohort study Participants: 1,979,509 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study included 1526 early adult-life (mean [SD] age, 36.7 [4.7] years; 821 [53.8%] female), 1943 midlife (mean [SD] age, 54.0 [5.8] years; 1010 [52.0%] female), and 885 late-life (mean [SD] age, 71.0 [4.5] years; 473 [53.4%] female) participants. 5 key findings →
Design: cohort study Participants: 1,526 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We evaluated 62 Automated speech analysis demonstrated high accuracy in differentiating FTD subtypes and provided insights into the neural basis of language impairments. 3 key findings →
Design: cross-sectional Participants: 16 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 14 participants (2 in part A and 12 in parts B and C) completed at least 12 months of follow-up and were included in the analyses. 5 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 13 592 participants (mean [SD] age, 58.34 [9.39] years; 7175 [52.8%] female), 6525 (48.0%) experienced possible childhood loneliness, and 565 (4.2%) reported childhood loneliness. 5 key findings →
Design: cohort study Participants: 592 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The MD is a scientifically supported dietary intervention with broad preventive and therapeutic benefits. 2 key findings →
Design: systematic review Participants: 84 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 62 RCTs comprising 200,068 participants were included. 5 key findings →
Design: meta-analysis Participants: 200,068 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. 4 key findings →
Participants: 215,970 Evidence: moderate
Full summary, score breakdown and related studies → Original source
After the clinical implementation of amyloid-β-targeting therapies for people with cognitive impairment due to Alzheimer's disease (AD), there is an urgent need to efficiently identify this patient population in primary care. 4 key findings →
Participants: 223 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Researchers at the University of Pittsburgh developed a new plasma p-tau217 test (using a different antibody than existing commercial tests) and validated it in 363 people, including some with genetic early-onset Alzheimer's mutations and community-dwelling older adults. 4 key findings →
Design: cross-sectional Participants: 363 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US. 4 key findings →
Design: modelling Participants: 31,028 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Individuals with cannabis use severe enough to require hospital-based care were at increased risk of a new dementia diagnosis compared with those with all-cause hospital-based care or the general population. 5 key findings →
Design: cohort Participants: 6,086,794 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The overall age and sex standardized incidence decreased between 2015 and 2021 from 3.5% to 2.8%. 2 key findings →
Design: cohort Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The results provide evidence for the efficacy and cost-effectiveness of extended nursing roles in dementia care, demonstrating that extended nursing roles reduce unmet needs and improve quality of life. 3 key findings →
Design: RCT Participants: 417 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Tau neurofibrillary tangles (NFTs) in the presence of amyloid-β (Aβ) plaques are required for the diagnosis of Alzheimer's Disease (AD) and closely track with cognitive impairment, yet cognitively normal aged individuals frequently exhibit NFTs arising from tau seed accumulation. 3 key findings →
Design: case-control Participants: 38 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
A polygenic score (PGS) for Alzheimer's disease (AD) was derived recently from data on genome-wide significant loci in European ancestry populations. 4 key findings →
Design: cohort Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cognitive performance in mild AD improved following tACS, with increased FC within cortical networks and between the hippocampus and specific cortical regions. 2 key findings →
Design: randomized controlled trial Participants: 23 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 44 844 patients invited to the APT Webstudy, the mean (SD) age was 64.7 (10.1) years, 25 447 (56.8%) were women, 25 044 (55.8%) had Medicaid insurance, 11 347 (25.3%) were Hispanic/Latino, 9526 (21.2%) were non-Hispanic Asian, 6044 (13.5%) were non-Hispanic Black, and 12 109 (27%) were non-Hispanic White. 2 key findings →
Participants: 844 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Age- and education-adjusted hazard ratios (HRs) for ADRD increased as neighborhood disadvantage increased, to 1.42 (95% confidence interval [CI] 1.06-1.91) in the most disadvantaged quintile compared to the least disadvantaged quintile, with a significant linear trend (p = 0.012). 5 key findings →
Design: longitudinal study Participants: 10,915 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →